30 related articles for article (PubMed ID: 17507321)
1. Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.
Duarte PS
J Nucl Med; 2021 Sep; 62(12):1833. PubMed ID: 34475238
[No Abstract] [Full Text] [Related]
2. Clinical management of HIV drug resistance.
Cortez KJ; Maldarelli F
Viruses; 2011 Apr; 3(4):347-78. PubMed ID: 21994737
[TBL] [Abstract][Full Text] [Related]
3. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
Demeter LM; DeGruttola V; Lustgarten S; Bettendorf D; Fischl M; Eshleman S; Spreen W; Nguyen BY; Koval CE; Eron JJ; Hammer S; Squires K
HIV Clin Trials; 2008; 9(1):11-25. PubMed ID: 18215978
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
5. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
[TBL] [Abstract][Full Text] [Related]
8. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Demeter LM; Shafer RW; Meehan PM; Holden-Wiltse J; Fischl MA; Freimuth WW; Para MF; Reichman RC
Antimicrob Agents Chemother; 2000 Mar; 44(3):794-7. PubMed ID: 10681363
[TBL] [Abstract][Full Text] [Related]
9. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
Haubrich RH; Jiang H; Swanstrom R; Bates M; Katzenstein D; Petch L; Fletcher CV; Fiscus SA; Gulick RM;
HIV Clin Trials; 2007; 8(2):63-7. PubMed ID: 17507321
[TBL] [Abstract][Full Text] [Related]
10. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
Freimuth WW
Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
[TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]